Sema4 to Participate at Three Upcoming Investor Conferences in November
Get Alerts SMFR Hot Sheet
Join SI Premium – FREE
STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences:
- Stifel 2021 Virtual Healthcare Conference
Formal presentation and 1x1s on Tuesday, November 16th, 2021 at 2:40 p.m. ET
- Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
Fireside chat and 1x1s on Thursday, November 18th, 2021 at 11:30 a.m. ET
- Jefferies London Healthcare Conference
1x1s on Friday, November 19th, 2021
Live and archived webcasts of the Stifel and Canaccord presentations will be available on the “Events” section of the Sema4 investor relations website at https://ir.sema4.com/.
About Sema4
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.
Investor Relations Contact:
Joel Kaufman
Sema4
[email protected]
Media Contact:
Radley Moss
Sema4
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Firm Capital Apartment REIT Reports Q2/2026 Results and Announces Name Change
- Orion180 Insurance Group Inc. Files Registration Statement for Proposed Initial Public Offering
- BioSyent Declares Third Quarter 2026 Dividend
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Stifel, Jefferies & Co, Twitter, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share